This week's roundup of Houston innovators includes Sarah "Sassie" Duggleby of Venus Aerospace, Youngro Lee of Brassica, and Le Dam of myAvos. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from rocket science to fintech — recently making headlines in Houston innovation.

Sarah "Sassie" Duggleby, CEO and co-founder of Venus Aerospace

Sarah "Sassie" Duggleby of Venus Aerospace joins the Houston Innovators Podcast this week. Photo courtesy of Venus

Sarah "Sassie" Duggleby and her husband were living in Japan and considering a trip back to Texas and wishing there was a faster option than a full day of international travel — with their kids, no less. That's when Andrew Duggleby told Sassie that there actually might be an engine that could do that.

Flash forward a few years, and the husband-wife team has built a company around that idea. Venus Aerospace, originally founded in California, relocated to Houston in 2021 to establish their company in an ecosystem with the tools to advance their tech — and give their employees a good work-life balance, Sassie Duggleby explains on the Houston Innovators Podcast.

"We knew we had to find a location where we could test our engine and still be home for dinner," she says on the show. "Our company vision is 'home for dinner.' We want to fly you across the globe and have you home for dinner. And, if you work for us, we want you home for dinner." Read more.

Youngro Lee has announced funding for his latest fintech endeavor. Photo courtesy

Youngro Lee is no stranger to shaking up the finance world with a new tech-based way of doing business. One of the founders of NextSeed, Lee's newest mission is providing "investment infrastructure as a service" with his company, Brassica, which just raised $8 million in seed funding.

“The future of finance will depend on the ability of trustworthy institutions to provide secure and seamless transitions between traditional financial services and web3 innovations while complying with strict regulations and still providing great customer experience,” says Lee in the news release.

Houston-based Mercury Fund led the round with several other investors participating. Read more.

Le Dam, CEO and founder of OptiChroniX

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

After years on the West Coast, Le Dam has returned to her adopted hometown of Houston — just in time to launch a new app dedicated to providing health resources and information to its users.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. Read more.

The myAvos app has been designed by behavioral health scientists to set users up for long, healthy lives. Photo via Canva

Houston innovator launches holistic health and cognitive care app

download now

Meet Laura. She’s not human, but she could be the key to your aging healthfully. She’s the digital wellness coach on myAvos, a groundbreaking app that launched this week from OptiChroniX.

Now meet Le Dam, the woman behind the app. Dam is a medical doctor, as well as CEO and co-founder of OptiChroniX. While practicing medicine in her birthplace of Australia, Dam realized that her life of prescribing medications to patients who were already sick was not how she had envisioned helping people. She knew that prevention, using the five pillars of healthy aging — nutrition, activity, sleep, health, and stress — was the way to keep patients fit and happy into their golden years.

She returned to California, where she lived after leaving Houston as a youth, to work at a startup with the goal of one day heading a company of her own. She met Swiss-based COO and co-founder, Rene Gilvert, on LinkedIn.

“He was looking for a medical doctor to join his startup,” Dam recalls. “We were so well aligned that we decided to join forces.” Now, the team works remotely in locations ranging from Dam’s home in Houston to Portugal.

When the pandemic happened, Dam took the opportunity to leave the Silicon Valley and work remotely from Houston, a return that she says was always her end goal.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. From there, Laura coaches them on what changes they can make to live healthier lifestyles. The app even reminds users when to take their medications and shares information with designated caregivers.

The myAvos app has a comprehensive approach to health. Screenshots via avos.health

The app has been designed by behavioral health scientists to understand why you’re not exercising enough or eating right and can offer personalized motivations to get users off the couch.

Right now, the focus is on potential dementia and cognitive impairment, says Dam, but in the future, myAvos will more holistically target all preventable chronic illnesses. But dementia is one of the major causes of disability among older people around the world and people living with it is expected to triple by 2050.

“If we can empower people with health literacy, we really believe we can prevent chronic disease,” says Dam. “Forty percent of dementia is preventable. A lot of these chronic diseases are preventable. Even diabetes can be reversible.”

And she points out that the changes that can be made to help cognitive health can affect other systems as well.

“We really want to empower the individuals,” Dam says. “If we can empower people with health literacy, we really believe we can prevent chronic disease.”

And myAvos is the key. The app is based on a subscription model, allowing users full access to a risk calculator, monthly cognitive assessments, personalized lifestyle guidance, and even fun brain games to keep them sharp. It may turn out that a visit with Laura a day will keep the doctor away long into your later years.

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.